Why Biotech Startups Are Choosing Australia

Every biotech leader faces the same equation. You need human data to unlock your next raise, but every month spent waiting for approvals burns runway. For a biotech startup, Australia can turn the slow, expensive stretch between the lab bench and first-in-human dosing into something faster and leaner. Here's what makes the country a serious option, and what it takes to set up here.



1. Your first trial can start sooner

Most early-phase industry trials in Australia run under the Clinical Trial Notification (CTN) scheme. Instead of waiting for a central regulator to review your application, you secure approval from an independent Human Research Ethics Committee and then notify the Therapeutic Goods Administration (TGA). In practice, studies can begin within weeks of ethics approval.

You also don't need a US Investigational New Drug (IND) application to run a trial in Australia. For a startup racing toward a proof-of-concept milestone, that can mean dosing your first participants while competitors elsewhere are still preparing regulatory files.

2. Your data travels with you

Speed only matters if the results count later. Australian trials follow international Good Clinical Practice (GCP) standards. The Australian Government notes that data generated here is routinely accepted by major regulators, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

In the US, FDA regulations allow foreign studies that weren't run under an IND to support later applications, provided they follow GCP and can be inspected. So the work you do in Australia can feed directly into your US and European development plans rather than sitting off to one side.

3. Your budget goes further

Early clinical work in Australia is widely regarded as cost-effective, and the Australian Government adds a powerful incentive on top. Under the R&D Tax Incentive, eligible companies with an aggregated turnover below A$20 million can claim a refundable tax offset equal to their corporate tax rate plus an 18.5% premium. Early-phase clinical trials generally qualify as core R&D activities.

4. A stable, well-regulated home for your IP

Investors care about where your intellectual property lives. Australia offers a transparent legal system, stable institutions and strong protection for intellectual property rights. That gives founders and their backers confidence that the value they create here is secure.

The country also has deep research capability. Its life sciences sector is one of the largest in the Southern Hemisphere, with thousands of organisations spanning discovery, translation, manufacturing and commercialisation.

5. A gateway to the Asia-Pacific

Australia sits in the same time zones as many of the world's fastest-growing healthcare markets. It has free trade agreements across the Indo-Pacific, including the Regional Comprehensive Economic Partnership (RCEP). For an international team, an Australian base can serve as a credible starting point for partnerships, trials and commercial relationships across the region.

6. Why Melbourne, Australia

Melbourne is home to one of the world's leading concentrations of medical research. The Melbourne Biomedical Precinct is the third largest biomedical precinct in the world and the largest in the Southern Hemisphere, bringing together hospitals, research institutes, universities and industry within a few city blocks. For an early-stage company, that proximity matters. Clinical trial sites, investigators, specialist service providers and potential partners are a short walk away rather than a long flight.


How Jumar helps you land and grow



Jumar Bioincubator is the front door for international biotech in Australia. Based inside CSL's global headquarters at the heart of the Melbourne Biomedical Precinct, Jumar can support international companies running clinical and R&D work in Australia . Residency at Jumar gives your team:

  • Ready-to-use lab and office space
  • A community of 30+ biotech ventures, plus wraparound services to support research translation
  • A mentor network and connections across the Australian biotech ecosystem
  • Easy access to nearby trial sites, hospitals, researchers and commercialisation partners

We're backed by partners including CSL, the University of Melbourne, the Walter and Eliza Hall Institute of Medical Research, Innovation Victoria and Cicada Innovations, so you arrive with a network rather than starting from scratch.

Ready to explore Australia for your next milestone? Enquire about International Residency at Jumar.


Frequently asked questions

Can a foreign biotech company run a clinical trial in Australia?

Yes. International companies regularly run trials here. The trial needs an Australian sponsor, which is often a local subsidiary of the overseas company.

Do I need FDA approval to run an early-phase trial in Australia?

No. Australian trials don't require a US IND. Studies run to Good Clinical Practice standards can later support FDA submissions, subject to FDA requirements.

How quickly can a trial start in Australia?

Under the CTN scheme, a trial can begin soon after ethics approval and notification to the TGA, often within weeks. Timelines depend on your study and sites.

Is my company eligible for the R&D Tax Incentive?

Eligibility depends on your structure, turnover and activities. Companies typically need to be incorporated in Australia. Check business.gov.au and speak with a specialist.

Why base a biotech startup in Melbourne?

Melbourne combines a dense cluster of hospitals, research institutes and universities with an established biotech community. Jumar's location inside CSL's global headquarters puts international teams at the centre of it.


Sources and further reading

Planning your first trial in Australia? Find out about International Residency at Jumar.